You just read:

Regenicin, Inc. Announces Scheduled Pre-IND Meeting with U.S. Food and Drug Administration (FDA) for its New Autologous Cultured Skin Substitute, NovaDerm®

News provided by

Regenicin, Inc.

Oct 12, 2016, 09:45 ET